MX2009010667A - Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. - Google Patents

Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.

Info

Publication number
MX2009010667A
MX2009010667A MX2009010667A MX2009010667A MX2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A
Authority
MX
Mexico
Prior art keywords
dimers
cancer agents
compounds
useful
smac mimetic
Prior art date
Application number
MX2009010667A
Other languages
English (en)
Inventor
Gunnar Hanson
Haizhou Sun
Original Assignee
Joyant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joyant Pharmaceuticals Inc filed Critical Joyant Pharmaceuticals Inc
Publication of MX2009010667A publication Critical patent/MX2009010667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención proporciona imitaciones de molécula pequeña del péptido SMAC que son compuestos similares a dímero o similares a trimero que tienen dos o tres dominios que contienen amida conectados por un enlazador. Estos compuestos son útiles para promover la apoptosis. La invención incluye composiciones farmacéuticas que comprenden tales compuestos y métodos para usarlos para tratar condiciones que incluyen cáncer y desórdenes autoinmunes.
MX2009010667A 2007-04-12 2008-04-11 Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. MX2009010667A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91147207P 2007-04-12 2007-04-12
US95249307P 2007-07-27 2007-07-27
PCT/US2008/060140 WO2008128121A1 (en) 2007-04-12 2008-04-11 Smac mimetic dimers and trimers useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
MX2009010667A true MX2009010667A (es) 2010-02-24

Family

ID=39864357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010667A MX2009010667A (es) 2007-04-12 2008-04-11 Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.

Country Status (10)

Country Link
US (2) US8642554B2 (es)
EP (1) EP2079309B1 (es)
JP (1) JP5454943B2 (es)
CN (1) CN101668426B (es)
AU (1) AU2008240153B2 (es)
BR (1) BRPI0810178A2 (es)
CA (1) CA2684169C (es)
MX (1) MX2009010667A (es)
NZ (1) NZ580313A (es)
WO (1) WO2008128121A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CA2598995C (en) * 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
BRPI0617751A2 (pt) 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7985735B2 (en) * 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
JP2010526834A (ja) 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
EP2367824B1 (en) * 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
SG175144A1 (en) * 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
JP5530514B2 (ja) 2009-06-11 2014-06-25 アッヴィ・バハマズ・リミテッド Ｈｃｖ感染を治療するための抗ウィルス化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2784076A1 (en) * 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9603889B2 (en) * 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN104710510A (zh) * 2013-12-12 2015-06-17 深圳先进技术研究院 Smac蛋白二聚拟合物及其鉴定方法
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
KR20230119040A (ko) 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP6953435B2 (ja) * 2016-05-09 2021-10-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二量体化合物
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
KR102173464B1 (ko) 2016-12-01 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
EP3573977A4 (en) 2017-01-26 2020-12-23 Arvinas Operations, Inc. EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CA3095494C (en) 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
AU2020252216A1 (en) 2019-04-05 2021-11-04 Hepagene Therapeutics (HK) Limited Bivalent antagonists of inhibitors of apoptosis proteins
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2022164900A1 (en) * 2021-01-27 2022-08-04 Unm Rainforest Innovations Pyrazole and pyrazoline-containing peptides, high throughput click libraries, and methods
EP4308095A1 (en) 2021-03-15 2024-01-24 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
SE9603466D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
US6916846B2 (en) * 2000-05-12 2005-07-12 Merck & Co. Inc. Coumermycin analogs as chemical dimerizers of chimeric proteins
CN101928288B (zh) 2000-11-02 2013-09-11 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
EP1740173A4 (en) 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
JP4691549B2 (ja) 2004-04-07 2011-06-01 ノバルティス アーゲー Ｉａｐの阻害剤
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CA2598995C (en) * 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
JP4954983B2 (ja) * 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物

Also Published As

Publication number Publication date
WO2008128121A1 (en) 2008-10-23
NZ580313A (en) 2011-11-25
CN101668426A (zh) 2010-03-10
US20140127155A1 (en) 2014-05-08
EP2079309B1 (en) 2015-11-11
AU2008240153A1 (en) 2008-10-23
EP2079309A4 (en) 2011-07-06
JP5454943B2 (ja) 2014-03-26
US8642554B2 (en) 2014-02-04
BRPI0810178A2 (pt) 2014-09-23
AU2008240153B2 (en) 2013-01-31
CA2684169C (en) 2012-06-19
CN101668426B (zh) 2014-01-15
EP2079309A1 (en) 2009-07-22
JP2010523717A (ja) 2010-07-15
CA2684169A1 (en) 2008-10-23
US20090104151A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MX2009010667A (es) Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
MX2008012053A (es) Promotores de apoptosis de molecula pequeña.
EP2493879A4 (en) DIMERE SMAC MIMETIKA
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
MX2012002434A (es) Conjugados de dimeros de pirrolo[1,4] benzodiazepina como agentes anticacerosos.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2020002542A (es) Variantes de interleucina-18 y metodos de uso.
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
IN2014CN04961A (es)
MX2014005411A (es) Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
DK2049529T3 (da) Substituerede diazepan-orexin-receptor- antagonister
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
CL2011001214A1 (es) Dimero de proteina similar a anticuerpo que comprende un decimo dominio de fibronectina de tipo iii (10fn3) que se une a igf-ir; unido covalentemente o no covalentemente con un 10fn3 que se une a egfr; composicion farmacéutica que lo comprende; uso de dicha composicion para tratar transtornos hiperproliferativo.
IN2012DN00640A (es)
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
MX2009011181A (es) Uso nuevo del hidroxitirosol.
EA201291460A1 (ru) Олигобензамидные соединения и их применение
EA201390813A1 (ru) Антитела и их применение
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.

Legal Events

Date Code Title Description
FG Grant or registration